$Cadrenal Therapeutics (CVKD.US)$
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted a recently published manuscript in the Journal of Cardiac Failure, evaluating the relationship between time in therapeutic range (TTR) management quality and clinical outcomes for left ventricular assist device (LVAD) patients. The findings emphasize the need for improved anticoagulation th...

Needs a clean break of .52 for any move upwards. Here are the levels to watch.
Larger Image: tradingview.com...
$Cadrenal Therapeutics (CVKD.US)$  

$Cadrenal Therapeutics (CVKD.US)$
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) has presented new data from the ARIES-HM3 trial at the ISHLT conference, showing the significant impact of anticoagulation quality in LVAD patients. The trial highlighted the deficiencies of warfarin and introduced tecarfarin, a novel VKA, as a potential replacement. T...

$Cadrenal Therapeutics (CVKD.US)$ Yes !!!

$Cadrenal Therapeutics (CVKD.US)$ Flying after market…

$Cadrenal Therapeutics (CVKD.US)$ This is what happens when i break my own rule! Oh well. I went in knowing that i was breaking my rule so i scaled in! Now i will average down a bit but still staying inside my original buy! GL